Viking Therapeutics (VKTX) Leases (2019 - 2025)
Viking Therapeutics (VKTX) has disclosed Leases for 7 consecutive years, with $85000.0 as the latest value for Q4 2025.
- For Q4 2025, Leases fell 91.53% year-over-year to $85000.0; the TTM value through Dec 2025 reached $85000.0, down 91.53%, while the annual FY2025 figure was $85000.0, 91.53% down from the prior year.
- Leases hit $85000.0 in Q4 2025 for Viking Therapeutics, down from $666000.0 in the prior quarter.
- Across five years, Leases topped out at $1.6 million in Q1 2022 and bottomed at $25000.0 in Q4 2021.
- Average Leases over 5 years is $908150.0, with a median of $1.0 million recorded in 2024.
- Year-over-year, Leases crashed 92.21% in 2021 and then surged 5572.0% in 2022.
- Viking Therapeutics' Leases stood at $25000.0 in 2021, then soared by 5572.0% to $1.4 million in 2022, then dropped by 20.59% to $1.1 million in 2023, then dropped by 10.92% to $1.0 million in 2024, then plummeted by 91.53% to $85000.0 in 2025.
- According to Business Quant data, Leases over the past three periods came in at $85000.0, $666000.0, and $780000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.